NFKBIA and amyotrophic lateral sclerosis: Emerging preclinical evidence highlights the extensive application of IκBα superrepressors delivered via exosome systems in various disease models, including RA, acute respiratory distress syndrome, alcohol-associated liver injury, sepsis-induced organ damage, kidney ischemia‒reperfusion injury, and amyotrophic lateral sclerosis (ALS) [455–460].